Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Oral Hexavalent Rotavirus Vaccine in Healthy Infants
NCT06967272Phase 2Recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hexavalent reassortant rotavirus attenuated live vaccine in rotavirus gastroenteritis (3 arms), sponsored by Sinovac Life Sciences. Primary endpoints: Immunogenicity of the investigational vaccine at different doses and Safety of the investigational vaccine at different dose. Started Jan 2025; status: recruiting.
02
Drugs
hexavalent reassortant rotavirus attenuated live vaccine
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT06967272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967272.